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Summary 
High concentrations of cocaethylene (EC), the ethyl ester of benzoylecgonxne, were 
measured in the blood of individuals who had concurrently used cocaine and ethanol 
Since the powerful reinforcing effects of cocaine appear to be dependent on mhlbiUon 
of dopamine reuptake in brain, we compared the effects of  EC on the doparmne 
uptake system and its behavioral effects with those of cocaine. EC was equlpotent to 
cocaine with respect to inhibition of binding of [3H]GBR 12395 to the dopanune 
reuptake complex, inhibition of [3H]dopamine uptake into synaptosomes and m its 
ability to increase extracellular dopamine concentratmn m the nucleus accumbens 
following ~ts systemic administratmn to rats. Moreover, in rats, EC and cocaine each 
increased locomotor actavity and rearing to the same extent following i.p 
admmistratmn. In self-administration stuches m primates, EC was approximately 
equipotent to cocaine in maintaining responding. The in vzvo formation of this 
active, transestenfied ethyl homolog of cocaine may contribute to the effects and 
consequences of combined cocaine and ethanol abuse 
In excess of 50% of cocaine abusers are reported to use ethanol (1,2), most often 
smaultaneously with cocaine (2). Anecdotal reports from cocaine abusers state that consumptaon 
of alcohol in the course of a cocaine binge prolongs the euphoria and/or ameliorates the dysphonc 
symptoms of acute abstinence. While these effects may be a consequence of the rewarding and 
sedating propernes of ethanol itself, recent evidence suggests that a metabolic interacuon between 
cocaine and ethanol may provide an additmnal mechanism (3-7). 
Smith (8) and Rafla and Epstein (9) each reported detection of traces of cocaethylene (EC), 
the ethyl ester of benzoylecgonine (Fig. 1A) m the unne of individuals who had concurrently used 
cocaine and ethanol. The assumpuon was that this compound resulted from the in v lvo 
transesterificataon of cocaine following its use in conjunction with ethanol. The biological 
significance of this Finding was not addressed at that tame. The demonstration of high plasma 
concentrations of EC, in some instances exceeding that of cocaine itself, led us to evaluate the 
neurochemical and behavioral properties of EC based on the possibihty that this metabolite n'ught 
be involved m the mechanisms and consequences of combined cocaine and ethanol abuse. 
Methods 
Postmortem samples from seven patients who had used both cocaine and ethanol were sent to 
us for inveslagation from the medical examaners laboratory in Dade county, where gas 
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chromatographic peaks, which were presumptively ldenufied as EC, had been observed in these 
samples and blood concentrations initially approximated using cocaine as a standard. We 
identified additional samples from Yale-New Haven Hospital Emergency Room patients for study 
on the basis of urine benzoylecgonine and blood alcohol analyses. 
Dru~ Analysis: Cocaine and EC concentrations were determined by reversed-phase ion pmrmg 
HPLC as previously reported (10). Blood sample preparation for gas chromatography-mass 
spectrometry (GC/MS) was as previously described for gas chromatographic analysis of cocaine 
(11). EC for use as an analyucal standard and for use m the neurochemical and behavioral 
studies, was synthesized by esterification of benzoylecgonme. Benzoylecgonine was refluxed for 
6-10 hours in ethanol through which dry HC1 gas had been passed. The ethanol was evaporated 
and the acid residue washed w~th hexane to remove any ethyl benzoate The residue was then 
suspended in carbonate buffer, pH 9.6, and the EC (but not benzoylecgonme) extracted into 
hexane. Following back extraction into acid and re-extraction into hexane, the product was 97- 
99% pure by HPLC and GC/MS analysis, and free of any contaminating cocaine. In some 
instances, EC was subsequently crystalhzed from ether as the hydrochlonde. A electron impact 
mass spectrum showed a molecular ion at m/e 317 and other major ions at m/e 196 and m/e 212 
which was consistent with pubhshed data (8). Corresponding cocaine ions were at m/e 182, m/e 
198 and rn/e 303. High resoluuon proton NMR confirmed the ethyl ester substltuuon for the 
methyl ester group of cocaine. 
Binding and Uotake: [3H]Doparmne uptake and [3H]GBR binding were performed essentmlly as 
described previously (12). This involved the preparation of P2 fraction from rat stnatum or 
nucleus accumbens. For [3H]dopamine uptake, the tissue was incubated with cocaine or EC and 
desipramme (100 nM) in Krebs phosphate buffer (pH 7.4) for 5 mm at 37°C before adding 
[3H]dopamine (40 nM, 37-40 Ci/mmol Dupont NEN). Two minutes later the uptake was 
terminated by rapid filtration through Whatman GF/C filters. The retained portion was washed 
and radioactivity trapped on the filter was counted. Non-specific binding was defined as the 
radioactwity on the filter following incubation of tissue and [3H]doparmne on ice. For [3HJGBR 
12935 binding, tissue was incubated at 4°C for 15 hr with cocaine or EC and [3H]GBR 12935 (2 
nM, 43 Ci/mmol, Dupont NEN, Boston, MA) in 50 mM Trls buffer containing 120 mM NaCI 
(pH 7.4). The incubation was terminated by vacuum filtration through Whatman GF/B filter 
paper. Each filter was rinsed and the radioactivity remaining on the filter was counted. Non- 
specific binding was defined with 10 I.tM mazindol. 
Microdlalysis in Rats (13-15): Concentric style rmcrodmlys:s probes were constructed using 
Cuprophan (Enka, West Germany) hollow fibers (300 ~tm I.d., 330 ~tm o.d.) housed in a section 
of 23 gauge stainless steel tubing with an exposed &alysls surface 1.5-2 mm long. The perfuslon 
buffer was (in mM): KC1 2 4, NaC1 137, CaC12 1.2, MgC12 1.2, NaH2PO4 0.9, Na2HP04 1.4, 
ascorbic acid 0.3, pH 7.4 Rats were anesthetized with chloral hydrate (400 mg/kg i.p.), and 
placed in a stereotaxlc apparatus in the flat skull position. The coordinates to which the tip of the 
dialysis probe were lowered vs the top of the skull at bregma were +1 7A, 1.3 L, and -8.3 V. 
Body temperature was monitored by a rectal temperature probe and maintained with a heating pad. 
Following each experiment, the brain was removed and stored in formalin for later sectioning and 
staining to verify probe placement In the nucleus accumbens. Determination of dopamine 
concentrauon was accomplished using HPLC with electrochermcal detection as previously (13). 
The routine hmit of detecuon was 2-3 fmols dopamme injected in a volume of 40 microliters. 
Rodent Behavior: The behavioral ratings of locomotor actavity and rearing were used to determine 
whether the drug treatments resulted in activation (16). Identical cardboard boxes were used as 
testing chambers for measunng rodent behavior. Quadrants were marked on the sides of the test 
chambers so that locomotor activity.could be measured by counting the crossings between 
sections. The rats were habituated to the test boxes for three hour periods two days before the 
test. Subjects were randomly assigned to one of three experimental groups destined to receive 
saline, cocaine or EC On the test day, each subject received its injection i.p. 5 mm before the 
test. The subjects were placed in the test box for 15 min. Behavioral ratangs were taken by one 
observer who was blind to the treatment Locomotor act:vity was defined as a crossing of 
quadrant markings on the rode of the test chamber Rearing was defined as lifting both forepaws 
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off the ground. 
Self-Administration by Primates: The reinforcing effects of EC were evaluated in three rhesus 
monkeys who were tr~ned to respond on levers and receive i.v. injections of cocaine on a fixed 
ratio 30 time out 45 sec schedule of drug delivery, as described previously (17). Each self- 
administration session consisted of four 25 rain components of drug availability, signalled by a 
red stimulus hght over the lever. Components were separated by 10 mm. blackout periods of no 
drug availability. The infumon duration, and hence the dose of drug dehvered, was different in 
each of the four sesmon components. The standard dose range for cocaine was 0.001 to 0.03 
mg/kg/injection. EC was substituted for cocaine m single dally sesmons over a dose range of 
0.001 to 0.03 mg/kg/injection m two monkeys, and over a dose range of 0.003 to 0.1 
mgtkg/injection in a third monkey. Data reported are for the observations of EC substitution and 
for the sessions of cocaine availability immediately preceding EC substitutaon. 
Statistics: Data were analyzed by ANOVA followed, where appropriate, by Newman-Keuls test 
with p<0.05 as the level of sigmficance. 
Results 
EC concentrations in the seven human postmortem samples ranged from 73 to 1447 ng/rnl 
(Table I) and the identity of the metabolite established by GC/MS (Figure 1). Note that m four 
instances, EC concentrations exceeded those of the parent compound. Ten of seventeen random 
emergency room blood samples in which the urine and plasma had been positive for 
benzoylecgonine and ethanol respectively, showed EC by HPLC. Of the seven EC negative 
samples, mx were either negatwe or showed less than 5 ng/ml of cocaine. Of fourteen additmnal 
samples that were positive by cocaine screening but were negatwe for ethanol, thirteen showed no 
EC and one sample showed a trace To exclude the possibility of in wtro artifact, we incubated 
400 ng/ml of both cocaine and benzoylecgonme in blood containing ethanol (500 mg/dl) at 37°C 
for one hour and at refrigerator temperature for 24 days. To approximate the gastric environment 
following alcohol ingestion, we incubated 4 g/dl alcohol with 500 ng/ml cocaine and 
benzoylecgonme m 0.1 M HC1 at 37°C for two hours. EC was not formed in any of these 
experiments. 
TABLE I 
Concentrations of EC, Cocaine and Ethanol in Postmortem Blood 
Subject EC Cocaine Ethanol 
ng/ml ng/ml mg/dl 
1 1447 4370 110 
2 376 290 190 
3 164 135 50 
4 109 140 140 
5 98 249 80 
6 73 34 240 
7 142 91 20 
On the basis of these findings, we initiated a series of studies in order to defme the 
pharmacological properties of EC. There was no significant difference between EC and cocaine 
in inhibiting the binding of the specific dopamine uptake blocker, [3H]GBR 12935 to rat striatal 
membranes (1(250 300 nM), (Figure 2B). Similarly, EC was also equipotent to cocaine (IC50 250 
nM) in inhibiting [aH]dopamine uptake into rat synaptosomes prepared from either striatum or 
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nucleus accumbens (Figure 2A). Following systemic administration of EC to rats, there was a 
significant increase (four-fold) in extracellular dopamine concentrations in the nucleus accumbens 
measured by microdialysis (Figure 3). These increases in dopamine levels were not significantly 
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FIG. 1 
A. Structures of cocaine and EC. 
B. GC/MS confirmation of EC: Upper trace, from a human plasma sample 
(subject 1, Table I); Lower trace, authentic EC. Note molecular ion at trde 317, 
and ions at m/e 196 and m/e 212. Corresponding ions for cocaine (not shown) are 
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A. Inhibition of [3H]dopamine uptake into rat stnatal synaptosomes by cocaine and 
EC. Each point represents the mean (+ SE) of 3 assays earned out in duplicate. 
B. Inhibition of binding of [3H]GBR 12935 to rat striatal membranes by cocaine 
and EC. Each point represents the mean of 2 assays camed out m trlphcate. 
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FIG. 3 
Extracellular dopamme levels in rat nucleus accumbens following acute L.v. 
injection of cocaine (1 mg/kg, n--4), EC (1 mg/kg, n=7), or saline (n=7). Mean (+ 
SE) baseline dopamme level corrected for probe recovery was 10.4 + 2.1 
fmol/microhter. 
In rats, EC and cocaine both potently increased locomotor acuvlty and rearing compared to 
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Behavior of rats following i.p. injection of cocaine (10 mg/kg, n=5), EC (10 
mg/kg, n=5) or saline (n=5). * and + denote sigmficant differences from saline 
treated group. 
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Rates of responding in rhesus monkeys were maintained by both i.v. cocaine and by EC when 
these drugs were delivered contingently on lever press responses. Although there was some 
individual variation in the doses of EC that maintained maximum rates of responding, each of the 
three monkeys showed rates of EC-mamtained responding that were similar to or slightly higher 
than rates maintained by cocaine (Fig. 6). On average, the maximum rate-maintaining dose of EC 
was 0.01 mg/kg/injectlon as compared to a dose of 0.03 mg/kg/injection of cocaine. A dose of EC 
above that maintaining maximum rates produced response decrements, a finding that is found with 
virtually all drugs that maintain self-administration behavior, including cocaine in this procedure 
(Skjoldager et al., submitted)• 
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FIG 5 
Mean rates of responding maintained by cocaine or EC in rhesus monkeys (n=3). 
Rate of responding maintained in each of the tested monkeys is also shown. Drugs 
delivered contingent on lever responses. 
Di scu sslon 
The high concentrations of EC found in human blood were comparable to and in many 
Instances well in excess of cocaine concentrations that are known to be associated with significant 
pharmacological activity (18, 19). EC was found in most samples associated with evidence of 
concurrent cocaine and ethanol use and was not present when the latter was absent. Those 
instances where EC was not present despite the occurrence of ethanol and benzoylecgonine, 
cocaine was either also absent from the blood or only present in trace amounts suggesting that EC 
may well have been completely cleared as well. In that instance where we saw a trace of EC (less 
than 10 ng/ml) despite the absence of alcohol, we suspect that the alcohol had been eliminated by 
the time the sample was obtained. Our incubation studies exclude the possibility of a storage 
artifact. EC is not a natural alkaloid of the coca leaf nor is street cocaine contaminated with EC. 
Removal of the methyl ester group of cocaine to form benzoylecgonine results in an almost 
complete loss of affinity for the monoamme uptake carrier (20); however, it is not known what 
effect other substatutions at this position have. Since EC has such close structural homology to 
cocaine, we postulated that it might have a similar spectrum of neurochemical and behavioral 
properties. We found that EC was equipotent to cocaine in its inhibition of specific ligand binding 
to the dopamine reuptake complex, inhibition of dopamine uptake into synaptosomes and in its 
ability to increase extracellular dopamine concentrations following administration to rats. The 
mechanism for the reinforcing properties of cocaine are thought to involve inhibition of dopamlne 
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reuptake with consequent elevation of synapttc dopamine levels m pathways mechatmg reward (20- 
28). The similar stimulation of rat locomotor activity and rearing observed after systemic 
administration of EC or cocaine, suggested that flus metabolite tmght share cocaine's 
psychostimulant properties. 
To put our neurochermcal f'mdlngs into perspecnve, it was essential to estabhsh whether EC 
was reinforcing in a primate model (29). The implications of our rodent data were confn'rned by 
the self-admlnistrauon studies m primates. EC was equlpotent to cocaine and showed a similar 
dose response curve m maintmning lever responding in rhesus monkeys. Following cocaine- 
ethanol abuse by humans, ethanol would be present m the body in addition to cocaine and EC 
The effects of these drugs in combmauon was not directly addressed by the described experiments 
Cocaine is rapidly elirmnated with an approximate plasma T 1/2 of one hour (30, 31) and its 
acute effects disappear even more rapidly. Depending upon its rate of fonnatton and elimination 
and its neurochemical properues, EC might be expected to add to cocaine's effects, prolong them 
and/or exhibit cross tolerance (32, 33) or cross sensit~zatlon (34) It might also better cross the 
blood brain bamer as a consequence of greater hydrophoblclty Since repeated use of cocaine and 
alcohol dunng a binge may be associated with exposure to recurrent pulses of cocaine and EC, 
sensinzataon and cross senmtlZatlon might contribute to the effects of this drug combination 
There have been relatively few pubhshed studies of the effects of combined cocmne and ethanol 
administration. One study (35) and two recent prehminary reports (36, 37) have indicated that 
some effects were enhanced and one indicated that subjectave effects were greater following 
adrmmstration of cocmne and ethanol in combinanon than after either drug alone (37) A recent 
preliminary report indicated that cocaine enhanced ethanol's threshold lowering effect on brain 
stimulation reward (38). This information is only suggesuve and there are other posmble 
explanataons for these observations including a &rect effect of ethanol on doparmne mediated 
reward pathways (39). In any event, further characterization of EC's neuropharmacology could 
enhance our understanding of the very prevalent problem of combined cocaxne-ethanol abuse 
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